Methods and systems for magnetically resonating both a subject and a substance administered to the subject

• US 8,421,457 B2
• Filed: 08/27/2009
• Issued: 04/16/2013
• Est. Priority Date: 08/27/2008
• Status: Active Grant

• Current Assignee: Applied Magnetics, LLC
• Original Assignee: Applied Magnetics, LLC
• Inventors: Cronin, John, Jacobson, Jerry I, Pottow, William, Braswell, Allen Jr., Rose, Christopher M
• Primary Examiner(s): Koval, Melissa
• Assistant Examiner(s): FETZNER, TIFFANY A
• Application Number:
  US12/548,802
• Publication Number:
  US 20100072996A1
• Time in Patent Office: 1,328 Days
• Field of Search: 324300-322, 600407-435, 600 13- 14, 382128-131, 607/9, 706/45
• US Class Current: 324/309
• CPC Class Codes: A61N 2/002 in combination with another treatment
• CPC Class Codes: A61N 2/02 using magnetic fields produced by coils, including single turn loops or electromagnets A61N2/12 takes precedence

Abstract

Embodiments of the current invention include a magnetic resonance system including a magnetic resonance device and a substance to be introduced to a subject in accordance with a treatment. Further embodiments of the current invention include a method of using a magnetic resonance system including administering a substance to a subject and providing magnetic resonance to the subject.

Claims

1. A method of using a magnetic resonance system comprising:

administering a substance to a subject, wherein the substance is a drug administered as part of a treatment regimen; and

providing a resonant magnetic field to the subject either before, concomitant with, or after administration of the substance;

monitoring the effect of the resonant magnetic field on the subject;

monitoring the effect of the substance on the subject; and

monitoring the interacting components of the resonant magnetic field and the substance on the subject concomitant with one another in order to determine how the application of the resonant magnetic field effects an absorption rate of the drug by the subject.

2. The method of claim 1, further comprising the initial step of generating a treatment regimen based on analyzing data associated with the subject.

3. The method of claim 2, wherein generating a treatment regimen based on analyzing data associated with the subject comprises the steps of:

analyzing data for positive prior treatment records of the subject; and

determining the treatment regimen that is the best match to the subject.

4. The method of claim 2, wherein generating a treatment regimen based on analyzing data associated with the subject comprises the steps of:

analyzing data for positive prior treatment records of like-situated subjects; and

determining the treatment regimen that is the best match to the subject.

5. The method of claim 2, wherein generating a treatment regimen based on analyzing data associated with the subject comprises the steps of:

analyzing subject population trends; and

determining the treatment regimen that is the best match to the subject.

6. The method of claim 1, wherein the substance is administered after the resonant magnetic field has begun to be provided.

7. The method of claim 1, wherein the substance is administered before the resonant magnetic field has begun to be provided.

8. The method of claim 1, wherein the substance is administered concomitant with providing the resonant magnetic field.

9. The method of claim 1, wherein the subject is monitored before, during, or after the treatment.

10. The method of claim 9, further comprising making the decision to continue or end treatment based at least in part on the monitoring of the subject.

11. The method of claim 9, further comprising adjusting the treatment regimen based at least in part on the monitoring of the subject.

12. The method of claim 1, further comprising the step of storing data concerning the treatment regimen.

13. A method of treating a human, animal, or plant subject with a magnetic resonance system, the method comprising:

administering a substance and resonant magnetic field to a subject, wherein the substance is a drug administered as part of a treatment regimen, and wherein the magnetic field is given before, after, or concomitant with the substance;

monitoring the effect of the resonant magnetic field on the subject;

monitoring the effect of the substance on the subject; and

monitoring the interacting components of the resonant magnetic field and the substance on the subject concomitant with one another in order to determine how the application of the resonant magnetic field effects an absorption rate of the drug by the subject.

14. The method of claim 13, wherein the subject has an indication or symptom of a medical condition.

15. The method of claim 14, wherein the substance is a beneficial substance, such that the substance has the capacity to ameliorate at least in part a symptom associated with the medical condition.

16. The method of claim 14 wherein the indication comprises at least one of Parkinson'"'"'s disease, diabetes, cancer, osteoarthritis, migraine, headache, fibromyalgia, chronic fatigue syndrome, pain, sports injury, accident injury, stiffness, back pain, diabetic neuropathy, high cholesterol, enlarged prostate, cardiac arrhythmia, tachycardia, atrial fibrillation, ventricular fibrillation, AIDS, Alzheimer'"'"'s disease, multiple sclerosis, amyotrophic lateral sclerosis, muscular dystrophy, attention deficit disorder, attention deficit hyperactive disorder, cerebral palsy, depression, or schizophrenia.

17. The method of claim 13, wherein the substance comprises at least one of Levodopa, beta blockers, cancer drugs, diabetes drugs, sulfonylureas, meglitinides, biguanides, thiazolidinediones, and alpha-glucosidase inhibitors, aspirin, ibuprofen, migraine drugs, pain relievers, Naproxen, cholesterol drugs, or prostate drugs.

18. The method of claim 13, wherein administering magnetic resonance comprises providing a resonant magnetic field with a flux density range of about 1 gauss to about 10⁻

50 gauss with the magnetic resonance system.

19. The method of claim 13, wherein administering magnetic resonance comprises providing a resonant magnetic field with a flux density range of about 10⁻

5 gauss to about 10<sup>−

12</sup> gauss with the magnetic resonance system.

20. The method of claim 13, wherein the indication comprises Parkinson'"'"'s disease.

21. The method of claim 20, wherein administering magnetic resonance comprises providing a resonant magnetic field with a flux density range of about 6.6×

10<sup>−

8</sup> gauss to about 7.8×

10<sup>−

8</sup> gauss with the magnetic resonance system.

22. The method of claim 20, wherein administering magnetic resonance comprises providing a resonant magnetic field with a frequency range of about 1.8 Hz to about 140 Hz with the magnetic resonance system.

23. The method of claim 14, wherein the indication comprises the medical condition of diabetes.

24. The method of claim 23, wherein administering magnetic therapy comprises providing a resonant magnetic field with a flux density range of about 5×

10<sup>−

7</sup> gauss to about 1×

10<sup>−

8</sup> gauss with the magnetic resonance system.

25. The method of claim 23, wherein administering magnetic resonance comprises providing a resonant magnetic field with a flux density range of about 5×

10<sup>−

7</sup> gauss to about 1×

10<sup>−

8</sup> gauss and a frequency range of from about 2.156 Hz to about 13.992 Hz with the magnetic resonance system.

26. A method of treating a subject with a magnetic resonance system that reduces the amount of a beneficial substance required to achieve a result or that increases the efficacy of an amount of the beneficial substance, the method comprising:

exposing the subject to a resonant magnetic field before, concomitant with, or after the administration of the beneficial substance, wherein the substance is a drug administered as part of a treatment regimen;

monitoring the effect of the resonant magnetic field on the subject;

monitoring the effect of the substance on the subject; and

monitoring the interacting components of the resonant magnetic field and the substance on the subject concomitant with one another in order to determine how the application of the resonant magnetic field effects an absorption rate of the drug by the subject.